



September 29, 2026

Company:	KYORIN Pharmaceutical Co., Ltd.
Representative:	Yutaka Ogihara Representative Director, President and CEO (Security Code: 4569, TSE Prime.)
Contact:	Shota Kikuchi Director, Corporate Planning
Telephone:	03-6374-9702

Launch of Vibegron for the Treatment of Overactive Bladder in Taiwan

KYORIN Pharmaceutical Co., Ltd. (hereinafter, "KYORIN") announced today that Marubeni Pharmaceuticals Taiwan Co., Ltd., a subsidiary of the Vibegron licensee Marubeni Pharmaceuticals Corporation (Head Office: Chuo-ku, Tokyo; President & COO: Shigeyuki Nishinaka; hereinafter, "Marubeni Pharmaceuticals"), has launched the overactive bladder (OAB) treatment Vibegron (brand name in Japan: Beova[®], hereinafter the "Product") in Taiwan on September 22, 2026 (brand name in Taiwan: GEMTESA[®]).

The Product is a once-daily oral selective β 3-adrenergic receptor agonist. It selectively acts on β 3 receptors in the bladder and relaxes the bladder, thereby enhancing bladder storage function and improving symptoms associated with OAB, including urinary urgency, urinary frequency and urge urinary incontinence.

In 2023, KYORIN granted Sumitomo Pharma Co., Ltd. exclusive rights to develop, manufacture and commercialize Vibegron in certain Asian regions. Subsequently, these rights were succeeded by Marubeni Pharmaceuticals.

Through this new launch and in partnership with Marubeni Pharmaceuticals, KYORIN aims to make the Product widely available across the contracted countries in Asia, continuing its mission of contributing to people's health.

The impact on business performance for the fiscal year ending March 2027 is to be negligible.

[Reference]

About Marubeni Pharmaceuticals

Established in 2025 with a mission to “contribute to a world where people can live every day with a smile,” Marubeni Pharmaceuticals is engaged in the sale of pharmaceuticals in China and Southeast Asia, a business inherited from Sumitomo Pharma Co., Ltd.. Marubeni Pharmaceutical defines “providing the medicines, information, and value that are needed in each region, regardless of whether they are new or old” as value innovation, and it aims to continue growing as a value innovator in order to achieve its mission. Marubeni Pharmaceuticals Taiwan Co., Ltd. is a subsidiary of Marubeni Pharmaceuticals, engaged in the sale of ethical drugs and provision and collection of information on products to/from medical professionals in Taiwan.

About Vibegron

Vibegron is a once-daily oral selective β_3 -adrenergic receptor agonist, discovered by Merck & Co., Inc., Rahway, N.J., U.S.A. (known as MSD outside of the United States and Canada) as a treatment for OAB. By selectively acting on β_3 receptors in the bladder, it relaxes the bladder during the storage phase and increases bladder capacity, thereby improving OAB symptoms, including urinary urgency, urinary frequency and urge urinary incontinence. KYORIN has obtained exclusive rights for developing, manufacturing and marketing of this drug in Japan and Asia* from Merck & Co., Inc., Rahway, N.J., U.S.A. In Japan, KYORIN and Kissei Pharmaceutical Co., Ltd. have jointly developed the agent under a co-development and co-marketing agreement and have been jointly marketing it under the brand name “Beova® Tablets 50mg” since November 2018. In March 2023, KYORIN granted Sumitomo Pharma Co., Ltd. exclusive rights to develop, manufacture and commercialize Vibegron in Taiwan, Hong Kong, Singapore, Indonesia and Vietnam. These rights were subsequently succeeded by Marubeni Pharmaceuticals.

* South Korea, Taiwan, Hong Kong, and 10 ASEAN countries

About OAB

OAB is a symptom syndrome characterized by urinary urgency, usually accompanied by urinary frequency and nocturia, with or without urge urinary incontinence. Concerns about access to toilets and disruption of sleep may interfere with daily life and reduce patients' QOL.

This document is for reference purposes only. In case of any discrepancy, the Japanese version shall prevail.